Processes Which Employ Non-Obvious Products

Slides:



Advertisements
Similar presentations
1 35 U.S.C nd paragraph Julie Burke TC1600 QAS
Advertisements

More on Restriction Practice Jim Housel SPE, Art Unit 1648 (703)
Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting October 8, 2002 William F. Smith Administrative Patent Judge Board of Patent Appeals.
1 35 U.S.C. § 112, first paragraph and the Wands Analysis Remy Yucel, SPE 1636 (571)
1 Rule 132 Declarations and Unexpected Results Richard E. Schafer Administrative Patent Judge Board of Patent Appeals and Interferences.
Julie Burke TC1600 QAS REJOINDER PRACTICE Julie Burke TC1600 QAS
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
1 Principles in Restriction Practice TC 1600 Anthony Caputa TC Practice Specialist (571)
Gene Therapy: Overcoming Enablement Rejections Karen M. Hauda Supervisory Patent Examiner Art Unit 1632 (703)
Prosecution Group Luncheon Patents August Proposed First-To-File Rules Add definitions in AIA to Rules Declarations for removing references based.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Examining Issues When.
Safekeeping of 35 U.S.C. 156 Extensions
Graham v John Deere Patent Law. Justice Tom Clark ( )
Intellectual Property Boston College Law School March 3, 2008 Patent - Nonobviousness.
Patent Overview by Jeff Woller. Why have Patents? Patents make some people rich – but, does that seem like something the government should protect? Do.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
Current and Future USPTO Practice RESTRICTION PRACTICES AT THE USPTO 1 © AIPLA 2015.
1 35 U.S.C. § 102(e): The Legislative Fix (S.320) and Serial Abandonment of Provisional Applications Stephen G. Kunin Deputy Commissioner for Patent Examination.
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
1 ANTICIPATION BY INHERENCY IN PRIOR ART James O. Wilson Supervisory Patent Examiner Technology Center 1600 USPTO (571)
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Applicant’s Reply: Applicant’s Reply: A TC1600 WORKSHOP A Workshop to Help Us Better Respond to Applicant’s Reply after FAOM A Workshop to Help Us Better.
Restriction & Double Patenting Mojdeh Bahar, J.D., M.A., CLP Chief, Cancer Branch Office of Technology Transfer National Institutes of Health U.S. Department.
Routine Optimization Jean Witz, tQAS, TC
To Restrict or Not To Restrict That Is The Question? Divided We Stand! Or Undivided We Stand!! By Joseph K. McKane SPE, Art Unit 1626.
Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.
35 U.S.C. 112, Second Paragraph Examination Memorandum Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
Josiah Hernandez Patentability Requirements. Useful Having utilitarian or commercial value Novel No one else has done it before If someone has done it.
Election of Species Joseph K. McKane SPE, Art Unit 1626 April 27, 2004.
1 When is it NOT Appropriate to Restrict? Julie Burke TC1600 QAS
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
New Sections 102 & 103 (b) Conditions for Patentability- (1) IN GENERAL- Section 102 of title 35, United States Code, is amended to read as follows: -`Sec.
Overview Validity of patent hinges on novelty, utility, and non-obviousness Utility generally not an issue Pre-suit investigation focuses on infringement,
New Ex Parte Appeal Rules Patent and Trademark Practice Group Meeting January 26, 2012.
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
Claims Proposed Rulemaking Main Purposes É Applicant Assistance to Improve Focus of Examination n Narrow scope of initial examination so the examiner is.
Margaret Polson Polson Intellectual Property Law, PC US Design Patents Overview.
Reviewing Common Themes in Double Patenting James Wilson, SPE 1624 TC
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. TC 1600 Biotech/Chem/Pharma.
2007 Revisions to Japanese Patent Law. 2 #1 Period for Filing Divisional Applications (A) BeforeBefore AfterAfter Notice of Allowance Divisional Application.
Double Patenting Deborah Reynolds SPE Art Unit 1632 Detailee, TC1600 Practice Specialist
1 Drivers for Implementation of TC 1600 Restriction Practice Action Plan: Public comments from bar groups, and customer partnerships starting before the.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. Kathleen Kahler Fonda Legal.
1 FY08 Restriction Petition Update and Burden Julie Burke Quality Assurance Specialist Technology Center 1600.
LYDON - TERMINAL DISCLAIMERS1 Terminal Disclaimer (TD) A Terminal Disclaimer states that the patent –will expire on the same date as a related.
Introduction to Intellectual Property Class of Sept
Obviousness-type Double Patenting
Prosecution Group Luncheon
Tim Saulsbury -- Continuations in Part
PATC Module 2 – Infringement/Validity
Next Gen Data Analytics To Support Licensing Strategies
Claims and Continuations Final Rule
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Patents IV Nonobviousness
Jerry Suva, Baker Botts LLP
Global Innovation Management Workout on Writing a Patent
Prosecution Luncheon Patent March 2017
Comparing subject matter eligibility in us and eu
Wisdom of the Board Ex parte PTAB Decisions Show Effective Arguments to Overcome an Obviousness Rejection Trent Ostler The content is exclusively the.
Stem Cells Peter Paras, Jr.
Update and Practical Considerations
PATC Module 2 – Infringement/Validity
Examination Issues: Immunology
Presentation transcript:

Processes Which Employ Non-Obvious Products Considering Ochiai, Brouwer and §103(b)

Treatment of Product and Process Claims in light of: In re Ochiai, 71 F.3d 1565, 37 USPQ2d 1127 (Fed. Cir. 1995) In re Brouwer, 77 F.3d 422, 37 USPQ2d 1663 (Fed. Cir. 1996) 35 U.S.C. §103(b)

Question? Can an otherwise conventional process or method be patented if limited to making or using a non-obvious product?

TEST The collective teachings of the prior art must have suggested to one of ordinary skill in the art that, at the time the invention was made, Applicants’ claimed invention would have been obvious.

Decision Use of per se rules is improper in applying the test for obviousness. There was no suggestion or motivation in the prior art to make or use non-obvious products. Rejections based upon S103(a) were overturned.

Impact Upon Examination RESTRICTION Product(s) & Process(es) may still be restricted. Product elected, rejoining the process is possible... WHEN Withdrawn process claims depend from the product claim. Process claim otherwise includes all of the limitations of an allowed product.

Rejoinder Considerations Process claims which are not commensurate in scope with allowed product. Process(es), if rejoined will be subject to examination for patentability in accordance with 37 C.F.R 1.104. - May have 112 1st or 2nd paragraph considerations. - Matter(s) of form

Biotechnological Processes only Effective Date of Inventions Ownership Term of Inventions Biotechnological Process Definition Timely election under provisions as of §103(b). 35 U.S.C. S103(b)